T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy.

Reder, Anthony T; Stuve, Olaf; Tankou, Stephanie K; Leist, Thomas P

Reder, Anthony T; Stuve, Olaf; Tankou, Stephanie K; Leist, Thomas P.

Afiliação

Reder AT; Department of Neurology, University of Chicago Medicine, Chicago, IL, USA.
Stuve O; Peter O'Donnell Jr. Brain Institute, UT Southwestern Medical Center, Dallas, TX, USA; VA North Texas Health Care System, Dallas VA Medical Center, Dallas, TX, USA.
Tankou SK; Mount Sinai Health System, New York, NY, USA.
Leist TP; Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA.

Mult Scler ; 29(6): 648-656, 2023 05.

Article em En | MEDLINE | ID: mdl-36440826

Assuntos

COVID-19; Esclerose Múltipla; Humanos; COVID-19/prevenção & controle; SARS-CoV-2; Linfócitos T; Esclerose Múltipla/tratamento farmacológico; Vacinas contra COVID-19; Vacinação; Anticorpos Antivirais

Palavras-chave

COVID-19; SARS-CoV-2; T cell; disease-modifying therapy; multiple sclerosis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 / Esclerose Múltipla Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google